Biolinks Search Engine Please support Team Biolinks by clicking on this banner. Every clickthrough counts.
ABS seeks to discover and commercialize products in the fields of cardiology and neurobiology.
The Company s enabling technology includes a patented Antigen-Free mouse colony which allows for the generation of highly specific monoclonal antibodies that cannot be acquired from conventional systems. In May 1997, Cell Genesys completed a merger with Somatix Therapy Corporation, another leading gene therapy company. The combined company has a broad portfolio of proprietary gene delivery technologies, multiple clinical stage product development programs and one of the largest patent estates in the gene therapy industry, all of which are critical in building a successful gene therapy business. Cell Genesys now has ongoing therapeutic programs at the clinical stage of development in cancer and AIDS as well as preclinical programs in cardiovascular and central nervous system gene therapy. Cell Genesys is developing both ex vivo and in vivo approaches to gene therapy.